Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAL vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
10 mg intravenously once daily
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (Cr Cl >90 m L/min). In moderate renal impairment (Cr Cl 30–59 m L/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for Cr Cl <60 m L/min.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Tralokinumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
92% bound primarily to human serum albumin; minor binding to alpha-1-acid glycoprotein (3%). Binding is concentration-independent over therapeutic range.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vd is 0.25 L/kg (range 0.2–0.3 L/kg), indicating distribution primarily into extracellular fluid. Vd increases to 0.4 L/kg in patients with edema or ascites.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability is 60–75% due to first-pass hepatic metabolism; 90–100% for intramuscular and subcutaneous routes.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment for Child-Pugh A; use with caution for Child-Pugh B and C, no specific dose recommendation
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for pediatric use; safety and efficacy not established
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; monitor renal function closely in elderly patients
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Hypersensitivity reactions (including anaphylaxis) have been reported; discontinue if serious reaction occurs.,Patients with parasitic (helminth) infections should be treated before initiating therapy; monitor during treatment.,Potential for increased risk of infections; consider risks in patients with chronic infections or history of recurrent infections.,Consider vaccination status prior to initiation; avoid live vaccines during treatment.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to tralokinumab or any excipients in the formulation.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No specific food interactions known; take with or without food. Grapefruit may alter metabolism; advise limiting grapefruit juice intake.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to Ig G1 transport across placenta, potential exposure in second and third trimesters. Theoretical risk of immunosuppression in the fetus.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
TRAL is a large monoclonal antibody likely excreted in breast milk in small amounts. M/P ratio not established. Limited data; consider risk-benefit; use caution.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended; weight-based dosing may need adjustment for maternal weight gain, but specific data lacking.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
TRAL is a novel anti-epileptic drug with linear pharmacokinetics; monitor for somnolence, dizziness, and weight gain; adjust dose in renal impairment (Cr Cl < 30 m L/min). Avoid abrupt discontinuation; taper over 2-4 weeks. Drug interactions: induces CYP3A4 and may reduce efficacy of oral contraceptives; valproate increases TRAL levels by 40%.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not stop suddenly without medical advice.,Avoid driving or operating heavy machinery until you know how this medicine affects you.,Report any rashes, swelling, or mood changes immediately.,Use effective contraception; this drug may reduce birth control effectiveness.,Avoid alcohol while taking this medication.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Concurrent use of lorazepam, a benzodiazepine, and sertraline, a selective serotonin reuptake inhibitor (SSRI), may result in additive central nervous system (CNS) depression, leading to enhanced sedation, dizziness, and psychomotor impairment. This interaction is primarily pharmacodynamic, involving potentiation of GABAergic effects by lorazepam and sertraline's modulation of serotonergic pathways, which can augment sedative effects. Clinically, patients may experience excessive drowsiness, reduced cognitive function, and increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Axitinib, a tyrosine kinase inhibitor used in renal cell carcinoma, is primarily metabolized by CYP3A4 and also inhibits CYP3A4 and CYP2D6. Sertraline, an SSRI antidepressant, is a substrate of CYP2D6 and to a lesser extent CYP3A4. Coadministration may lead to decreased clearance of sertraline, resulting in elevated sertraline plasma concentrations and increased risk of serotonin-related adverse effects such as serotonin syndrome, QT prolongation, or gastrointestinal disturbances."
"Mequitazine, a first-generation H1-antihistamine, inhibits CYP2D6 and CYP3A4, the primary enzymes responsible for the metabolism of sertraline, a selective serotonin reuptake inhibitor (SSRI). This inhibition can significantly reduce sertraline clearance, leading to increased plasma concentrations, which may elevate the risk of dose-dependent adverse effects such as serotonin syndrome, QT prolongation, and central nervous system depression. Patients may present with symptoms including confusion, tachycardia, hyperthermia, or arrhythmias, particularly at higher doses or in those with underlying risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAL vs ACTIQ, answered by our medical review team.
TRAL is a Opioid Analgesic that works by Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAL and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAL is: 10 mg intravenously once daily. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAL and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAL is classified as Category C. TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to IgG1 transport across placenta, potential ex. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.